The FDA’s CTGTAC voted that the data from the IGNYTE trial are evaluable and clinically meaningful for RP1/nivolumab in advanced cutaneous melanoma.
|Videos|April 20, 2021
Dr. Rapisuwon on Biologic Differences Between Mucosal and Cutaneous Melanoma
Author(s)Suthee Rapisuwon, MD
Suthee Rapisuwon, MD, discusses the biologic differences between mucosal and cutaneous melanoma.
Advertisement
Suthee Rapisuwon, MD, medical oncologist, MedStar Health, discusses the biologic differences between mucosal and cutaneous melanoma.
The initiation events differ between mucosal melanoma and cutaneous melanoma, says Rapisuwon. Unlike in cutaneous melanoma, BRAF mutations are not often the phylogenetic event in mucosal melanoma, Rapisuwon explains.
However, patients with mucosal melanoma often harbor neurofibromatosis type 1 mutations, genetic aberrations in chromosomes 5 through 12, and KIT mutations, says Rapisuwon. Moreover, these abnormalities often serve as organizing events for tumorigenesis, concludes Rapisuwon.
Advertisement
Related to this article
The Cellular, Tissue, and Gene Therapies Advisory Committee will review Replimune’s twice-rejected BLA for RP1 plus nivolumab in advanced melanoma.
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
A research team from Huntsman Cancer Institute at the University of Utah showed a pathway-targeted therapy that could be an effective melanoma treatment.
Advertisement
Advertisement
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
FDA Grants Priority Review to Subcutaneous Amivantamab in Head and Neck Cancer
3
Dr Barot on the FDA Approval of Palbociclib/Trastuzumab ± Pertuzumab in HER2+ Breast Cancer
4
Dana-Farber Researchers Identify CDK8 as a Potential Therapeutic Target for Alveolar Rhabdomyosarcoma
5